Table 2

Distribution of patients and disease characteristics between treatment groups



No endocrine treatment (n=206)Endocrine treatment without OS (n=2018)Endocrine treatment with medical OS (n=282)Endocrine treatment with BSO (n=234)P value
n (%)n (%)n (%)n (%)
Follow-up
 Median37.164.160.167.3
 Range0.6–105.90.5–115.13.1–108.36.2–108.4
 IQR7.5–58.248.9–82.749.2–77.751.9–84.4
Age at diagnosis
 Median (mean)45 (43.9)45(44)43 (42.2)45 (44.1)<0.001*
 Range20–5620–6024–5926–55
 IQR41–4840–4937–4840–48
Year of diagnosis
 201040 (7.5)404 (76.2)41 (7.7)45 (8.5)<0.001
 201131 (5.8)421 (78.4)39 (7.3)46 (8.6)
 201237 (7.4)373 (74.9)46 (9.2)42 (8.4)
 201342 (7)442 (74)69 (11.6)44 (7.4)
 201456 (9.7)378 (65.4)87 (15.1)57 (9.9)
Family history†
 No85 (7)922 (75.7)116 (9.5)95 (7.8)0.202
 Yes114 (7.9)1041 (72)157 (10.9)133 (9.2)
 Unknown75596
Live children
 No62 (8.3)556 (74.2)79 (10.5)52 (6.9)0.263
 Yes144 (7.2)1462 (73.4)203 (10.2)182 (9.1)
Histology
 Any ductal no lobular166 (7.6)1606 (73.4)232 (10.6)184 (8.4)0.008
 Any lobular no ductal19 (7.1)190 (70.9)34 (12.7)25 (9.3)
 Lobular and ductal8 (4.5)135 (76.7)11 (6.3)22 (12.5)
 Inflammatory0 (0)9 (75)2 (16.7)1 (8.3)
 Other13 (13.5)78 (81.3)3 (3.1)2 (2.1)
Grade†
 G127 (13.8)155 (79.1)7 (3.6)7 (3.6)<0.001
 G235 (5.5)478 (75.8)72 (11.4)46 (7.3)
 G3113 (6.7)1229 (72.6)186 (11)166 (9.8)
 Unknown311561715
LN pos exact†
 No163 (9.3)1319 (75.5)141 (8.1)123 (7)<0.001
 Yes43 (4.3)698 (70.4)140 (14.1)110 (11.1)
 Unknown111
Stage (unknown removed)
 I135 (9.8)1048 (76.1)107 (7.8)87 (6.3)<0.001
 II47 (5.6)634 (74.9)86 (10.2)79 (9.3)
 III16 (5.2)193 (62.9)55 (17.9)43 (14)
Chemotherapy
 No138 (13.5)729 (71.5)88 (8.6)65 (6.4)<0.001
 Yes68 (4)1289 (74.9)194 (11.3)169 (9.8)
HER-2 targeted
 None183 (7.9)1698 (73.6)242 (10.5)183 (7.9)<0.001
 Trastuzumab17 (5.2)256 (78)25 (7.6)30 (9.1)
 Trastuzumab+other6 (5.7)64 (60.4)15 (14.2)21 (19.8)
  • Percentages are calculated by row.

  • *p values for continuous variables are calculated using Kruskal-Wallis test, if not otherwise labeled.

  • †For these variables the unknowns are not considered in the percentage reporting and the test for p value.

  • BSO, bilateral salpingo-oophorectomy; HER-2, human epidermal growth factor receptor 2; IQR, interquartile range; LN, lymph node; OS, ovarian suppression.